what i found interesting in the presentation was that neuren wants to keep commercial rights for NA 2591 and licence out row 2591 rights first (opposite to trof). possibly, they could package trof and 2591 ROW rights together as one deal that might attract bigger pharma.
if this is lucrative enough, it (with the Acadia money) could finance a couple of phase 3 trials.
what i found interesting in the presentation was that neuren...
-
- There are more pages in this discussion • 6,435 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.76 |
Change
0.150(1.10%) |
Mkt cap ! $1.758B | |||
| Open | High | Low | Value | Volume |
| $13.60 | $14.00 | $13.51 | $5.043M | 365.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3816 | $13.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.78 | 2834 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |